The GALAXY Programme
The GALAXY ProgrammeTM is designed to confirm the hypothesis that the statin with the best effects on the atherogenic lipid profile and beneficial changes on inflammatory markers will deliver profound benefits on atherosclerosis in turn leading to the best reductions in cardiovascular morbidity and mortality.
The GALAXY Programme have, in total, recruited over 63,000 subjects in more than 55 countries around the world.
Page tools
Publication updates
Register for the alert service and receive updates when
publications onrosuvastatin are published.
Efficacy
Clinical research
The best surrogate data will translate into the best clinical outcomes seen so far with statin
therapy.